AMPH

#2482
Amphastar Pharmaceuticals, Inc.
21.7100 USD
+1.54%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
21.5100
21.7600
년간 변동
17.0300
29.5200
일일 변동
+1.54%
월간 변동
+14.69%
6달 변화
-10.95%
년간 변동율
-10.95%
이전 종가
21.3800
Open
21.5200
Bid
Ask
Low
21.5100
High
21.7600
양
228
Open full chart

Financials

Overview 성명 Statistics
Quarterly Annual
  • Market Capitalization 984.9864 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
13.19
Price to sales ratio
1.79

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

뉴스